Phase 1 · NCT04823208
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
- ClinicalTrials.gov ID
- NCT04823208
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 64
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 20 Years – 70 Years
- Locations
- 4 sites · Japan
- Study start
- 24 May 2021
- Primary completion
- 23 Jun 2022
- Study completion
- 23 Jun 2022
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 22 Aug 2022
Endpoints
Primary
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943; PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943; Change from Baseline in Mean Daily Plasma Glucose (PG); Change from Baseline in Glycated Hemoglobin (HbA1c); Change from Baseline in Fasting Glucose; Change from Baseline in Body Weight